Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Sintilimab in Advanced Non Clear Cell Renal Cell Carcinoma
NCT05220267Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and sintilimab in non-clear cell renal cell carcinoma (nccRCC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival up to 2 years. Started Feb 2022; status: active, not recruiting.
02
Drugs
anlotinibsintilimab
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT05220267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220267.